Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.30
TBIO's Cash to Debt is ranked lower than
81% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. TBIO: 0.30 )
Ranked among companies with meaningful Cash to Debt only.
TBIO' s 10-Year Cash to Debt Range
Min: 0  Med: 4.17 Max: No Debt
Current: 0.3
Equity to Asset 0.35
TBIO's Equity to Asset is ranked lower than
80% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. TBIO: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
TBIO' s 10-Year Equity to Asset Range
Min: -0.46  Med: 0.70 Max: 0.95
Current: 0.35
-0.46
0.95
F-Score: 4
Z-Score: -8.13
M-Score: -2.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -55.22
TBIO's Operating margin (%) is ranked lower than
70% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. TBIO: -55.22 )
Ranked among companies with meaningful Operating margin (%) only.
TBIO' s 10-Year Operating margin (%) Range
Min: -63.96  Med: -27.60 Max: -1.53
Current: -55.22
-63.96
-1.53
Net-margin (%) -44.13
TBIO's Net-margin (%) is ranked lower than
68% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.06 vs. TBIO: -44.13 )
Ranked among companies with meaningful Net-margin (%) only.
TBIO' s 10-Year Net-margin (%) Range
Min: -136.16  Med: -32.03 Max: -2.06
Current: -44.13
-136.16
-2.06
ROE (%) -139.90
TBIO's ROE (%) is ranked lower than
85% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.27 vs. TBIO: -139.90 )
Ranked among companies with meaningful ROE (%) only.
TBIO' s 10-Year ROE (%) Range
Min: -167.63  Med: -31.09 Max: -3.63
Current: -139.9
-167.63
-3.63
ROA (%) -38.61
TBIO's ROA (%) is ranked lower than
70% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.44 vs. TBIO: -38.61 )
Ranked among companies with meaningful ROA (%) only.
TBIO' s 10-Year ROA (%) Range
Min: -72.54  Med: -23.02 Max: -2.7
Current: -38.61
-72.54
-2.7
ROC (Joel Greenblatt) (%) -251.49
TBIO's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. TBIO: -251.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TBIO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -393.55  Med: -50.66 Max: -4.92
Current: -251.49
-393.55
-4.92
Revenue Growth (3Y)(%) -22.50
TBIO's Revenue Growth (3Y)(%) is ranked lower than
83% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. TBIO: -22.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TBIO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -23.5  Med: -11.90 Max: 9.9
Current: -22.5
-23.5
9.9
EBITDA Growth (3Y)(%) -4.70
TBIO's EBITDA Growth (3Y)(%) is ranked lower than
59% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. TBIO: -4.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TBIO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -54.7  Med: -1.80 Max: 71
Current: -4.7
-54.7
71
EPS Growth (3Y)(%) -8.50
TBIO's EPS Growth (3Y)(%) is ranked lower than
60% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. TBIO: -8.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TBIO' s 10-Year EPS Growth (3Y)(%) Range
Min: -58.5  Med: -8.50 Max: 179.5
Current: -8.5
-58.5
179.5
» TBIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.34
TBIO's P/B is ranked higher than
83% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. TBIO: 1.34 )
Ranked among companies with meaningful P/B only.
TBIO' s 10-Year P/B Range
Min: 0.97  Med: 2.20 Max: 704
Current: 1.34
0.97
704
P/S 0.39
TBIO's P/S is ranked higher than
96% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. TBIO: 0.39 )
Ranked among companies with meaningful P/S only.
TBIO' s 10-Year P/S Range
Min: 0.39  Med: 1.26 Max: 3.51
Current: 0.39
0.39
3.51
Current Ratio 1.16
TBIO's Current Ratio is ranked lower than
85% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. TBIO: 1.16 )
Ranked among companies with meaningful Current Ratio only.
TBIO' s 10-Year Current Ratio Range
Min: 0.96  Med: 2.50 Max: 18.01
Current: 1.16
0.96
18.01
Quick Ratio 0.97
TBIO's Quick Ratio is ranked lower than
85% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. TBIO: 0.97 )
Ranked among companies with meaningful Quick Ratio only.
TBIO' s 10-Year Quick Ratio Range
Min: 0.67  Med: 1.87 Max: 17.35
Current: 0.97
0.67
17.35
Days Inventory 69.84
TBIO's Days Inventory is ranked higher than
54% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.06 vs. TBIO: 69.84 )
Ranked among companies with meaningful Days Inventory only.
TBIO' s 10-Year Days Inventory Range
Min: 73.18  Med: 112.99 Max: 369.56
Current: 69.84
73.18
369.56
Days Sales Outstanding 128.43
TBIO's Days Sales Outstanding is ranked lower than
88% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. TBIO: 128.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
TBIO' s 10-Year Days Sales Outstanding Range
Min: 66.74  Med: 99.97 Max: 152.44
Current: 128.43
66.74
152.44

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.31
TBIO's Price/Median PS Value is ranked higher than
90% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. TBIO: 0.31 )
Ranked among companies with meaningful Price/Median PS Value only.
TBIO' s 10-Year Price/Median PS Value Range
Min: 0.33  Med: 1.12 Max: 13.94
Current: 0.31
0.33
13.94
Earnings Yield (Greenblatt) (%) -47.80
TBIO's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. TBIO: -47.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TBIO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -48.44  Med: 28.70 Max: 39
Current: -47.8
-48.44
39

Analyst Estimate

Dec15
Revenue(Mil) 27
EPS($) -2.06
EPS without NRI($) -2.06

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:A, ROP, GRMN, HXGBY, TRMB » details
Traded in other countries:TGKN.Germany,
Transgenomic Inc was incorporated in Delaware on March 6, 1997. The Company is a biotechnology company advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. Its operations are organized and reviewed by management along its product lines and presented in the following two complementary business segments: Laboratory Services and Genetic Assays and Platform. In Laboratory Services: its laboratories engaged in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. Its Patient Testing laboratories located in New Haven, Connecticut and Omaha, Nebraska are certified under the Clinical Laboratory Improvement Amendment ("CLIA") as high complexity laboratories and its Omaha facility is also accredited by the College of American Pathologists ("CAP"). Its laboratories employ genomic testing service technologies, including ICE COLD-PCR technology. ICE COLD-PCR is a proprietary platform technology that can be run in any laboratory with standard PCR technology and that enables detection of multiple unknown mutations from virtually any sample type including tissue biopsies, blood, cell-free DNA ("cfDNA") and circulating tumor cells ("CTCs") at levels greater than 1,000-fold higher than standard DNA sequencing techniques. In enetic Assays and Platforms: its proprietary product is the WAVE System, which has applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. It also distributes bioinstruments produced by other manufacturers ("OEM Equipment") through its sales and distribution network. The Company also distributes bioinstruments produced by other manufacturers ('OEM Equipment') through its sales and distribution network. Service contracts to maintain installed systems are sold and supported by its technical support personnel. The installed WAVE base and some OEM Equipment platforms generate a demand for consumables that are required for the continued operation of the bioinstruments. It develops, manufactures and sells these consumable products. In addition, it manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Competitors in these areas, among others, include Applied Biosystems, Qiagen, Roche, Sequenom and Illumina. Competition for some of its non-WAVE consumable products comes from numerous well-diversified life sciences reagent providers, including, among others, Invitrogen, Qiagen, Roche, Stratagene and Promega. The Company is subject to a variety of federal, state and municipal environmental and safety laws based on its use of hazardous materials in both manufacturing and research and development operations.
» More Articles for TBIO

Headlines

Articles On GuruFocus.com
Transgenomic, Inc. Reports Second Quarter 2009 Results Aug 12 2009 

More From Other Websites
TRANSGENOMIC INC Financials Aug 27 2015
Transgenomic Adds Asia Distributors for Its ICEme™ Kits That Enable Liquid Biopsy-Based Genomics... Aug 27 2015
Transgenomic Adds Asia Distributors for Its ICEme™ Kits That Enable Liquid Biopsy-Based Genomics... Aug 27 2015
Transgenomic Showcases How Multiplexed ICE COLD-PCR™ is Advancing Precision Medicine in Address at... Aug 20 2015
Transgenomic Launches New MX-ICP Panel for Lung Cancer That Accurately Detects Key EGRF Mutations in... Aug 19 2015
10-Q for Transgenomic, Inc. Aug 17 2015
TRANSGENOMIC INC Files SEC form 10-Q, Quarterly Report Aug 14 2015
TRANSGENOMIC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 13 2015
Transgenomic Reports Second Quarter 2015 Financial Results Aug 13 2015
Q2 2015 Transgenomic Inc Earnings Release - After Market Close Aug 13 2015
Transgenomic to Hold Second Quarter Financial Results Conference Call on August 13, 2015 at 5:00PM... Aug 12 2015
Transgenomic Establishes Clinical-Commercial Advisory Board to Help Optimize Use of Multiplexed ICE... Aug 10 2015
Transgenomic Announces Pilot Clinical Study of its Multiplexed ICE COLD-PCR™ Liquid Biopsies with... Aug 05 2015
Tuesday's Mid-Day Movers: Iran's Nuclear Deal Reached; Micron Technology Bid, Box Inc And More Jul 14 2015
One Factor Driving Transgenomic (TBIO) Stock Up Jul 14 2015
Transgenomic Launches Most Comprehensive Genetic Test for Diagnosis of Leukodystrophy Jul 14 2015
TRANSGENOMIC INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Unregistered Sale... Jul 07 2015
Transgenomic Launches Ultra-High Sensitive ICEme™ Mutation Enrichment Kits Enabling Turbocharged... Jul 01 2015
TRANSGENOMIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale... Jul 01 2015
Transgenomic Announces Private Placement Financing Jul 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK